DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0116341 A1 Askari Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0116341 A1 Askari Et Al US 2013 0116341A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0116341 A1 Askari et al. (43) Pub. Date: May 9, 2013 (54) N-VVO GELLING PHARMACEUTICAL filed on Aug. 31, 2010, provisional application No. PRE-FORMULATION 61/332,197, filed on May 7, 2010. (75) Inventors: Syed H. Askari, San Jose, CA (US); Publication Classification George Horng, Millbrae, CA (US) (51) Int. Cl. (73) Assignee: MEDICUS BIOSCIENCES, LLC, San A647/34 (2006.01) Francisco, CA (US) (52) U.S. Cl. CPC ...................................... A61K47/34 (2013.01) (21) Appl. No.: 13/696,032 USPC ........................................ 514/772.3; 524/879 (22) PCT Fled: May 6, 2011 (57) ABSTRACT (86) PCT NO.: PCT/US11A35643 Provided herein are in vivo gelling pharmaceutical pre-for mulations forming biocompatible hydrogel polymers that are S371 (c)(1), polymerized in Vivo and kits comprising at least one nucleo (2), (4) Date: Jan. 15, 2013 philic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one thera Related U.S. Application Data peutic agent. The biocompatible hydrogel polymer is bioab (60) Provisional application No. 61/387.841, filed on Sep. Sorbable and releases the therapeutic agent at a target site, 29, 2010, provisional application No. 61/378,730, avoiding systemic exposure. Patent Application Publication May 9, 2013 Sheet 1 of 2 US 2013/011 6341 A1 FIGURE 1 W Comparing DDP and DCP Elution - EF-daily SSS - - - - - - -& & CP-Eily iš. Š........................&. 3.s :S SS S. S. S S aSNCP-2x 3ily \sŠs ws S. ass s t S Y Yo Y V V v YY S v Y&\ssic Yxas &s SS ^ws assass & & Sas SSssssssssssssss $WasaSSS Xwas Patent Application Publication May 9, 2013 Sheet 2 of 2 US 2013/011 6341 A1 FIGURE 2 xyYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY: Comparing Cumulative Elution with Time 90 c.c. SS &S US 2013/011 6341 A1 May 9, 2013 N-VVO GELLING PHARMACEUTICAL pound is a glycol, trimethylolpropane, pentaerythritol, hexa PRE-FORMULATION glycerol, or tripentaerythritol derivative. In preferred embodiments, the first compound is a pentaerythritol or hexa CROSS-REFERENCE glycerol derivative. In certain embodiments, the first com pound further comprises one or more polyethylene glycol 0001. This application claims the benefit of U.S. Provi sections. In some embodiments, the first compound is sional Application No. 61/387,841, filed Sep. 29, 2010, U.S. selected from the group consisting of ethoxylated pentaeryth Provisional Application No. 61/378,730, filed Aug. 31, 2010, ritol ethylamine ether, ethoxylated pentaerythritol propy and U.S. Provisional Application No. 61/332,197, filed May lamine ether, ethoxylated pentaerythritol amino acetate, 7, 2010, each of which are incorporated herein by reference in ethoxylated hexaglycerol ethylamine ether, ethoxylated their entirety. hexaglycerol propylamine ether, and ethoxylated hexaglyc erol amino acetate. In certain embodiments, the first com BACKGROUND OF THE INVENTION pound is selected from the group consisting of trimethylol 0002 Every year millions of people undergo systemic propane trimercaptoacetate, trimethylolpropane tri-3- treatments, such as chemotherapy for cancers, inflammatory mercaptopropionate, pentaerythritol tetramercaptoacetate, diseases, and chronic conditions. Systemic treatments, in pentaerythritol tetra-3-mercaptopropionate, ethoxylated tri which medications are injected or absorbed into the blood methylolpropane trimercaptoacetate, ethoxylated trimethy stream an circulated throughout the body, are currently the lolpropane tri-3-mercaptopropionate, ethoxylated pen only viable option to reach the site of these diseases even taerythritol tetramercaptoacetate, and ethoxylated though in most cases the disease is localized in a specific trimethylolpropane tri-3-mercaptopropionate. In some organ. However, the systemic approach produces toxic side embodiments, the molecular weight of the first compound is effects, such as profound nausea and vomiting, immunosup between about 1000 and 20000. pression and risk or life threatening infections, anemia, hair 0006. In certain embodiments, the electrophilic group is loss, kidney toxicity, and nerve damage. For many cancer an epoxide, N-Succinimidyl Succinate, N-Succinimidylglut patients the toxicity potential is so severe that chemotherapy arate, N-Succinimidyl Succinamide or N-Succinimidylglut cannot be given. In some instances, patients die of the side aramide. In some embodiments, the second compound is a effects rather than from the cancer. trimethylolpropane, glycerol, diglycerol, pentaerythritol, Sorbitol, hexaglycerol, tripentaerythritol, or polyglycerol SUMMARY OF THE INVENTION derivative. In preferred embodiments, the second compound 0003 Provided herein are in vivo gelling pharmaceutical is a trimethylolpropane, pentaerythritol, or hexaglycerol pre-formulations, biocompatible hydrogel polymers, in vivo derivative. In some embodiments, the second compound fur polymerized biocompatible hydrogel polymers, and kits for ther comprises one or more polyethylene glycol sections. In preparing in vivo gelling pharmaceutical pre-formulations, certain embodiments, the second compound is selected from biocompatible hydrogel polymers, and in vivo polymerized the group consisting of ethoxylated pentaerythritol Succinim biocompatible hydrogel polymers. The pre-formulations and idyl Succinate, ethoxylated pentaerythritol Succinimidylglu hydrogel polymers comprise a mixture of compounds that tarate, ethoxylated pentaerythritol Succinimidylglutaramide, safely undergo polymerization to form a biocompatible ethoxylated hexaglycerol Succinimidyl Succinate, ethoxy hydrogel polymer at a target site. Using a minimally invasive lated hexaglycerol Succinimidyl glutarate, and ethoxylated delivery system (e.g., endoscopic or image guided), the poly hexaglycerol Succinimidyl glutaramide. In some embodi meric hydrogel formulation is delivered to the target site, ments, the second compound is selected from the group con where the pre-formulation solidifies into a biocompatible sisting of Sorbitol polyglycidyl ether, polyglycerol polygly hydrogel polymerata predetermined time to remain at the site cidyl ether, diglycerol polyglycidyl ether, glycerol of delivery. In some embodiments, the biocompatible hydro polyglycidyl ether, and trimethylolpropane polyglycidyl gel polymer comprises one or more therapeutic agents that ether. In certain embodiments, the molecular weight of the are released over time from the hydrogel polymer at the target second compound is between about 1000 and 20000. site, limiting exposure of healthy cells to the therapeutic 0007. In some embodiments, the therapeutic agent is inde agent. In certain embodiments, the biocompatible hydrogel pendently selected from the group consisting of an anticancer polymer degrades over time and is bioabsorbed. agent, an antiviral agent, an antibacterial agent, antifungal 0004. In one aspect provided herein is an in vivo gelling agent, an immunosuppressant agent, an hemostasis agent, pharmaceutical pre-formulation, comprising (a) at least one and an anti-inflammatory agent. water soluble first compound comprising more than one 0008. In certain embodiments, the gelling time of the bio nucleophilic group, (b) at least one water soluble second compatible hydrogel polymer is controlled by the pH of the compound comprising more than one electrophilic group, (c) aqueous buffer. In some embodiments, the gelling time is an aqueous buffer in the pH range of 5.0 to 9.0; and (d) between about 20 seconds and 5 minutes. In certain embodi optionally, one or more therapeutic agents; wherein mixing ments, the pH of the aqueous buffer is from about 6.9 to about the first compound, the second compound, and the optional 7.9. In some embodiments, the pH of the aqueous buffer is therapeutic agent in the aqueous buffer and delivering the about 7.4. In certain embodiments, the biocompatible hydro mixture to a target site in the human body generates the in gel polymer gels at a predetermined time. In some embodi Vivo gelling pharmaceutical pre-formulation Such that the in ments, the biocompatible hydrogel polymer is a bioabsorb Vivo gelling pharmaceutical pre-formulation at least in part able polymer. In certain embodiments, the biocompatible polymerizes and gels at the target site to form a biocompatible hydrogel polymer is bioabsorbed within about 1 to 70 days. In hydrogel polymer. Some embodiments, the biocompatible hydrogel polymer is 0005. In some embodiments, the nucleophilic group is a substantially non-bioabsorbable. In certain embodiments, the thiol or amino group. In certain embodiments, the first com in vivo gelling pharmaceutical pre-formulation further com US 2013/011 6341 A1 May 9, 2013 prises a radiopaque material or a pharmaceutically acceptable ethoxylated hexaglycerol propylamine ether, ethoxylated tri dye. In certain embodiments, the radiopaque material is methylolpropane tri-3-mercaptopropionate, ethoxylated selected from Sodium iodide, potassium iodide, barium Sul hexaglycerolamino acetate. fate, tantalum, VISIPAQUE(R), OMNIPAQUER, or 0012. In some embodiments, the electrophilic group is an HYPAQUE(R), or combinations thereof. epoxide, N-Succinimidyl Succinate, N-Succinimidyl glut arate, N-Succinimidyl Succinamide, or N-Succinimidylglut 0009. In some embodiments, the therapeutic
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.1] European Commission
    MTC eHealth DSI [eHDSI v2.2.1] European Commission - Master Translation/Transcoding Catalogue Responsible : eHDSI Solution Provider PublishDate : Thu Jun 01 17:03:48 CEST 2017 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]
  • Tranexamic Acid for Treatment and Prophylaxis of Bleeding and Hyperfibrinolysis
    consensus report Wien Klin Wochenschr DOI 10.1007/s00508-017-1194-y Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis Ingrid Pabinger · Dietmar Fries · Herbert Schöchl · Werner Streif · Wolfgang Toller Received: 29 February 2016 / Accepted: 14 March 2017 © The Author(s) 2017. This article is an open access publication. Summary Uncontrolled massive bleeding with sub- 1966. TXA is of utmost importance in the prevention sequent derangement of the coagulation system is and treatment of traumatic and perioperative bleed- a major challenge in the management of both surgi- ing due to the resulting reduction in perioperative cal and seriously injured patients. Under physiologi- blood loss and blood transfusion requirements. The cal conditions activators and inhibitors of coagulation following article presents the different fields of appli- regulate the sensitive balance between clot formation cation of TXA with particular respect to indications and fibrinolysis. In some cases, excessive and diffuse and dosages, based on a literature search and on cur- bleeding is caused by systemic activation of fibrinol- rent guidelines. ysis, i. e. hyperfibrinolysis (HF). Uncontrolled HF is associated with a high mortality. Polytrauma patients Keywords Trauma·Surgery·Bleeding·Hyperfibri- and those undergoing surgical procedures involving nolysis · Tranexamic acid organs rich in plasminogen proactivators (e. g. liver, kidney, pancreas, uterus and prostate gland) are at Introduction a high risk for HF.Antifibrinolytics, such as tranexamic acid (TXA) are used for prophylaxis and treatment of Massive bleeding after surgical interventions or se- bleeding caused by a local or generalized HF as well as vere trauma continues to be one of the most frequent other hemorrhagic conditions.
    [Show full text]
  • Study Protocol Celerion Project No.: CA19169 Aronora Inc
    Celerion Project No.: CA19169 Sponsor Project No.: EWE-17-01 US PIND No.: PTS #PS003017; CRMTS #10353 A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of E-WE Thrombin as an Intravenous Bolus in Healthy Adult Subjects GCP Statement This study is to be performed in full compliance with the protocol, Good Clinical Practices (GCP), and applicable regulatory requirements. All required study documentation will be archived as required by regulatory authorities. Confidentiality Statement This document is confidential. It contains proprietary information of Aronora Inc., and/or Celerion. Any viewing or disclosure of such information that is not authorized in writing by Aronora Inc., and/or Celerion is strictly prohibited. Such information may be used solely for the purpose of reviewing or performing this study. CA19169 (EWE-17-01) Final Protocol Amendment 2 14May2018 E-WE Thrombin Page 2 Sponsor Project No.: EWE-17-01 SAD Study Protocol Celerion Project No.: CA19169 Aronora Inc. US PIND No.: PTS #PS003017; CRMTS #10353 1. PROTOCOL REVISION HISTORY DATE/NAME DESCRIPTION 14May2018 Final Protocol, Amendment 2: by Caroline Engel Following on FDA recommendations, the following changes were made to the protocol: 1. The dosing interval between the sentinel group and the remaining subjects was revised to at least 28 days in Cohort 1 and 14 days in the remaining cohorts. The protocol was updated throughout to reflect this change. 2. The following study stopping rules were added to bullet number 5 in Section 10.4.1.4 Dose Escalation and Stopping Rules: I.
    [Show full text]
  • WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61L 24/04 (2006.01) A61K 9/127 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/US20 13/0406 19 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 10 May 2013 (10.05.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/646,227 11 May 2012 ( 11.05.2012) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/669,577 9 July 2012 (09.07.2012) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 61/785,358 14 March 2013 (14.03.2013) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: MEDICUS BIOSCIENCES, LLC [US/US]; ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Malaysian Statistics on MEDICINES-271010.Indd
    MALAYSIAN STATISTICS ON MEDICINES 2007 CHAPTER 7 | USE OF ANTIHAEMORRHAGICS Lim Y.S.1, Wong S.P.1, Goh A.S.2, Chang K.M.1 1. Ampang Hospital, 2. Pulau Pinang Hospital Antihaemorrhagics did not differ much in usage trends from 2006 to 2007. The most used class of antihaemorrhagics was still the class of amino acids, namely tranexamic acid (0.07 DDD/1000 population/day), owing to its safety profile, readily available forms as capsules and injection ampoules as well as cheap price. Tranexamic acid was used for local fibrinolysis and menorrhagia. The Australian data showed a higher consumption for tranexamic acid with 0.11 DDD/1000 population/day in 2007.1 Aprotinin, a proteinase inhibitor (0.0003 DDD/1000 population/ day), was indicated for the reduction or prevention of blood loss in patients undergoing open heart surgeries only.2 Aprotinin was apparently more used in the private sector than in the public sector as so happened in reality. Although recombinant Factor VIIa or eptacog alfa (activated) was one of the few agents available for haemophilia A or B patients with inhibitors to coagulation factors VIII or IX, recent years had seen it being used in excessive bleeding incidences unmanageable by conservative treatments or blood coagulation factors during minor or major surgical even critical neuro-surgical or obstetrics-gynaecological procedures.3 However, its overall usage was still very minimal at 0.0001 DDD/1000 population/day, perhaps due to its exorbitant price tag of ~RM 2700 per vial of 1.2mg. The length of stay in critically ill patients that need reversal of coagulopathy and the costs of hospitalisation should be added to the total charges that would count to the cost-effectiveness of eptacog alfa.4 In fact, eptacog alfa (activated) was little used in both sectors of the healthcare industry.
    [Show full text]
  • Germany Haemotherapy Guidelines
    Bundesärztekammer (German Medical Association) Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives Published by: Executive Committee of the German Medical Association on the recommendation of the Scientific Advisory Board 4th revised edition ii Notice: Medical science and the public health service are subject to continuous development, entailing that all statements regarding them can only be in accordance with the state of knowledge current at the time of publication. The utmost care was taken by the authors in compiling and verifying the stated recommendations. Despite diligent manuscript preparation and proof-reading of the typeset, occasional mistakes cannot be ruled out with certainty. Regarding the choice and dosage of drugs, the reader is requested to consult the manufacturer’s package insert and expert information and, in case of doubt, to draw on a specialist. Liability for any diagnostic or therapeutic application, medication or dosage lies with the reader. Accordingly, the German Medical Association does not assume responsibility and no subsequent or any other damage that result in any way from the use of information contained in this publication. This publication is copyright-protected. Any unauthorized use therefore requires prior written permission from the German Medical Association. Copyright © 2009 by German Medical Association iii This English translation and printing of the Cross-sectional Guidelines was funded by the organisers of the European Symposium on “Optimal Clinical Use of Blood Components”, April 24th–25th 2009, Wildbad Kreuth, Germany (European Directorate for the Quality of Medicines & Health Care, Strasbourg; LMU Klinikum der Universität, München; Paul- Ehrlich-Institut, Langen). The organisers gratefully acknowledge the excellent translation by Ms.
    [Show full text]
  • Antifibrinolytic Drugs for Treating Primary Postpartum Haemorrhage (Review)
    Cochrane Database of Systematic Reviews Antifibrinolytic drugs for treating primary postpartum haemorrhage (Review) Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012964. DOI: 10.1002/14651858.CD012964. www.cochranelibrary.com Antifibrinolytic drugs for treating primary postpartum haemorrhage (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 Figure1. ..................................... 10 RESULTS....................................... 14 Figure2. ..................................... 16 Figure3. ..................................... 17 DISCUSSION ..................................... 21 Figure4. ..................................... 23 AUTHORS’CONCLUSIONS . 23 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 24 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 38 Analysis 1.1. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH, Outcome 1 Maternal mortality due
    [Show full text]